A 37-year-old man whose ten years of headaches, weakness, nasal congestion and near-fainting episodes vanished after he stopped a common thyroid medication has been diagnosed with a systemic allergy to acacia gum, an inert filler used in pharmaceuticals. The case, published as a case report in Allergy, Asthma & Clinical Immunology, is presented by its authors as the first documented instance of an allergic reaction caused by ingesting this widely used excipient.
Acacia gum, also labelled E414, is a water-soluble emulsifier derived from the Acacia senegal tree. It is added to foods and medicines for its stabilizing properties. According to the report’s background section, hypersensitivity reactions to the gum have mainly been reported in occupational settings, where workers inhale or handle the powder, and these reactions are thought to be IgE-mediated, although the specific molecular epitope responsible remains unknown. No cases of allergic reactions due to ingestion had previously been documented in the literature.
The patient, who had hypothyroidism and migraines, endured a decade of episodic headaches, weakness, nasal congestion and presyncope, the sensation of being about to faint. His clinical workup was extensive and included sinus surgery, immunotherapy, treatments for migraine and suspected seizures, and dietary changes. None of these interventions resolved his symptoms.
The turning point came when his symptoms disappeared after he discontinued Synthroid, a branded levothyroxine product used to treat his hypothyroidism. That resolution raised suspicion that the reaction was linked not to the active hormone but to an inactive ingredient. Acacia gum, listed among Synthroid’s inactive components, was identified as a potential trigger. When the man switched to a compounded levothyroxine formulation that did not contain acacia gum, his symptoms resolved and stayed resolved.
Confirmatory testing pointed squarely at the excipient. Skin prick testing was negative to both Synthroid and pure levothyroxine. Intradermal testing, which injects a small amount of allergen beneath the skin surface, produced a positive response to Synthroid, with a 6 mm wheal and 12 mm flare, and a striking 50 mm wheal to acacia gum, while pure levothyroxine again tested negative. This dissociation, positive to the branded tablet and the gum but negative to the hormone itself, is consistent with an excipient-driven reaction rather than an allergy to levothyroxine.
Oral challenges provided further evidence. A self-administered exposure to acacia gum induced throat tightness, shortness of breath, tongue swelling and near-syncope within 15 minutes. Under supervision, a placebo-controlled oral challenge to Synthroid reproduced symptoms just 10 minutes after the patient ingested 7.5 micrograms, only 10 percent of his usual dose. An oral challenge with 0.5 grams of acacia gum elicited similar symptoms. The report notes these were challenge results in a single patient, not measures of how commonly such reactions occur in the wider population.
The authors argue the case carries a broader lesson: excipients should be considered as potential allergens in patients with unexplained or multisystem symptoms, particularly when reactions do not match the known side-effect profile of the active drug. Because inactive ingredients vary between manufacturers and between commercial and compounded preparations, a medication change that seems trivial can remove, or introduce, the component actually responsible for a reaction.
The report also underscores a practical point for clinicians assessing drug-related reactions: formulation differences between commercial and compounded medications matter, and a patient who tolerates one levothyroxine product may react to another that contains a different filler. As a single case report, the findings cannot establish how frequently acacia gum ingestion causes systemic reactions, and the authors note that the absence of prior reported cases does not mean the risk is new. But the documented challenge responses, they conclude, show that ingestion of acacia gum may cause systemic allergic reactions even without prior reported cases, and that awareness of inactive ingredients deserves a place in the evaluation of unexplained allergic symptoms.
Subject of Research: Systemic hypersensitivity to acacia gum, a pharmaceutical excipient, documented in a single case report
Article Title: Systemic hypersensitivity to acacia gum as a pharmaceutical excipient: a case report
Article References: Bou Rjeily, M., Abow-Mohamed, I., Denis-D’Ortun, S., & Kwok, M. (2026). Systemic hypersensitivity to acacia gum as a pharmaceutical excipient: a case report. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/s13223-026-01057-7
Image Credits: AI Generated
DOI: 10.1186/s13223-026-01057-7
Keywords: acacia gum, pharmaceutical excipient, drug allergy, hypersensitivity, levothyroxine, Synthroid, case report, oral challenge, intradermal testing, IgE-mediated allergy, excipient allergy, Allergy Asthma & Clinical Immunology
News Source: Ophelia Keating. (October 29, 2026). Acacia Gum in Thyroid Pills Triggered Decade-Long Allergic Symptoms, Case Report Finds. Scienmag.
